VSTM News and Press, Verastem Inc.

2026-06-24 11:15:06 ET Leonid Timashev from RBC Capital issued a price target of $15.00 for VSTM on 2026-06-24 13:37:00. The adjusted price target was set to $15.00. At the time of the announcement, VSTM was trading at $4.325. The overall price target consensus is at $15...

2026-06-23 20:32:09 ET Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers June 23, 2026 4:30 PM EDT... Read the full article on Seeking Alpha For further details see: Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101...

Broad anti-tumor activity observed with VS-7375 across dose levels in multiple solid tumors, including pancreatic, colorectal, and lung cancers Early evidence of anti-tumor activity with either anti-EGFR therapy or standard-of-care chemotherapy supports broad development strategy includin...

2026-06-17 14:43:08 ET The last time I spoke about Verastem, Inc. ( VSTM ) it was with a Seeking Alpha article entitled " Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play ." With respect to this article, I mentioned that the company was already in the process o...

90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis 6-month overall survival rate was 86%; follow-up continues and survival data continue to mature Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medic...

TARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer A cohort in TARGET-D 201 will also evaluate the combination of VS-7375 and cetuximab for frontline treatment of metastatic pancreatic canc...

Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trial Company to host investor conference call and webcast on Tuesday, June 23, 2026, at 4:30 pm ET Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advanci...

Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026 Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday,...

2026-05-26 10:20:04 ET Ironwood Pharmaceuticals: A Contrarian Buy Opportunity Ironwood Pharmaceuticals: Still A Profitable Opportunity GeneDx: Disappointing Q1 Creates Another Turnaround Opportunity Notable healthcare headlines for the week: UnitedHealth, Boston ...